Physician profile
Vidhya L Kumar
NPI 1376033506
$667.37
in general payments reported to CMS, 2019-2025
15 companies · $237 in 2025
The $237 reported for 2025 was more than what 78% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $43.81 · 2022: $121 · 2023: $146 · 2024: $120 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $502.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Greer Laboratories, INC. | $109.81 | 2025 | Oralair |
| Sanofi Pasteur INC. | $78.22 | 2022-2024 | |
| Corium, LLC | $72.68 | 2022-2025 | Azstarys |
| Seqirus USA INC | $58.37 | 2023-2025 | Flucelvax Quadrivalent, Flucelvax |
| Cranial Technologies, INC | $58.09 | 2022-2023 | Doc Band |
| Sobi, INC | $50.68 | 2022-2023 | |
| Azurity Pharmaceuticals, INC. | $45.66 | 2025 | Alvesco |
| Sanofi-Aventis U.S. LLC | $45.32 | 2024-2025 | |
| Kaleo, INC. | $31.63 | 2021-2022 | |
| Cumberland Pharmaceuticals, INC. | $28.44 | 2024 | Kristalose |
| Supernus Pharmaceuticals, INC. | $23.29 | 2024 | Qelbree |
| Biomerieux INC | $23.00 | 2025 | Biofire Spotfire Control Station |
| Glaxosmithkline, LLC. | $15.40 | 2021 | |
| Ironshore Pharmaceuticals INC. | $13.59 | 2021 | |
| Merck Sharp & Dohme LLC | $13.19 | 2023 | Vaxelis, Gardasil 9, Vaxneuvance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vidhya Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.